About the Study
This study is designed to evaluate the safety and effectiveness of an investigational drug, TSND-201, in treating PTSD symptoms. TSND-201 is a new study drug that could affect how the brain works, which could cause changes in mood, awareness, thoughts, feelings, or behavior. TSND-201 is thought to create a strong sense of emotional openness, reduced fear, and increased understanding of feelings, which could be helpful for people with PTSD. TSND-201 is an “investigational” drug because it has not been approved by the Food and Drug Administration (FDA).
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 67% chance you will receive the study treatment and a 33% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
You will be in this study for approximately 16 weeks which will include a screening period, a treatment period, and a follow up period. The study will require up to 16 in-clinic visits. If you qualify and choose to participate, you may be compensated for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.